"Big flip" or "an empty"? New preparation plus holding, Gilead multi-directional exploration...

Guide: New dosage forms, combination medications, and more, Gilead reveals several research trends in Redsiwereedsewe for nearly two days, news, yesterday, India's generic drug has just been approved, today Gilead announced a clinical trial of Redsiweinative inhaling agents, with the intention of early intervention to avoid hospitalization of patients, and Gilead also revealed its exploration of many directions ..New dosage! Redseve inhalers enter the testJune 22, 2020 U.Stime, Gilead Scienceannounced that it has obtained fda approval from the U.SFood and Drug Administration (FDA) and will begin trials of Remdesivir inhalersA trial of healthy volunteers is scheduled to be screened this week and is expected to begin its study of patients with new coronavirus pneumonia in AugustDaniel, chairman and chief executive ofGilead Sciences, said: "Inhalation agents will be administered through nebulizers, which will make it possible for patients to take their medication simply in the early stages of the disease, outside the hospitalThis is also important to help prevent a pandemic of the disease"
Redsewey, diversified exploration, into? Defeat?currently, Gilead's antiviral drug Remdesivir has been approved only by Japan's Ministry of Health, Labour (MHLW) for the treatment of COVID-19Although the drug has been granted emergency use authorizations or expanded in many countries and regions around the world, there is still little critical experimental evidenceAs of now, Gilead's trial on Redseve's treatment of the new coronavirus is shown below: "
map for Gilead's research trial on Redseweand and the expected release time of the data
including early sympathy drugs, 2 SIMPLE trials, two simple trials in Hubei, and ni-blind trials in NiH, are lacking key evidence, and the results will always be weakened for a variety of reasons Authoritative, even double-blind test results are diametrically opposed (specific reasons click reading: ) results are not satisfactory, and Gilead has chosen to continue to explore Redsewe in many ways, including evaluating interventional therapy in early stages of the disease, treatment of critically ill patients in combination with other therapies, pediatric research, and the development of different dosage forms first, a first phase of the Remdesivir inhaler will be tested this week , Gilead is also exploring ways to improve patient outcomes through a combination of Redsiwe and other therapies It is reported that Redsivir and JAK inhibitor baricitinib, as well as IL-6 receptor antagonist tocilizumab trials are expected in the next few months again, Gilead will conduct redsseway trials in pregnant women and end-stage nephropathy patients Last week, it was also announced that it would begin clinical trials of children as an effective drug found during the outbreak, the urgent need for accurate test results are convincing, although many trials, but the key results have not yet been produced, the feasibility of the above multi-directional exploration test is not ignored But before the vaccine was available, Redsewe was still a much-anticipated drug and for the benefit of patients around the world, as of June, Gilead had donated all of its existing Redsiweand and had entered into non-exclusive voluntary licensing agreements with a total of nine generic drugdealers in India, Pakistan and Egypt Indian generics approved, pricing announced on June 21, june 21, the Drug Administration of India (DCGI) accelerated the approval of two Redsivir generics developed by Cipla and Hetero to treat suspected or laboratory-confirmed COVID-19, hospitalized adults and children with severe illnesses Cipra's product, called Cipremi, is priced at Rs 3,000-4,000 ($39-52) per dose Mr Hedlund's product, called Covifor, is priced at Rs 5,000-6,000 ($65-$78) per dose Under current guidelines from the Indian government, a patient with COVID-19 may need five to six doses, which means the total cost of antiviral drugs is as low as $195 India's current new crown outbreak is very serious, drug data query, the latest single day new 149,000 cases, a cumulative total of 440,000 confirmed cases, 14,000 deaths Two local Indian companies have prepared enough inventory and plan to launch their products within a week the two-dimensional code below can be accessed to the latest data
in addition to Redsewe, India on June 20 has approved Favravavir (trade name: FabiFlu) for the treatment of patients with mild to moderate COVID-19 This is the first new coronary pneumonia treatment approved in India approval of the three drugs, providing more Indian patients with much-needed treatment options and easing the pressure on the country as a whole finally, thanks to all the medical workers, look forward to Redsewe has the exact results of the trial, but also look forward to the vaccine as soon as possible, the outbreak will end as soon as possible, the drug network will continue to pay attention to the progress of research and the progress of vaccine development .. .